Compare Novartis AG (NVS) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs SoundHound AI Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while SoundHound AI Inc trades at $5.39 (market cap $2.45B). The key difference: Novartis AG is far larger — about 109.6× SoundHound AI Inc's market cap, and Novartis AG pays a 3.31% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and SoundHound AI Inc for 23 Days on average.
| NVS | SOUN | |
|---|---|---|
Market Cap | $268.57B | $2.45B |
Volume | 1,532,573 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $168.62 | $21.40 |
52-Week Low | $121.80 | $5.39 |
Typical Hold Time | 82 Days | 23 Days |
Enterprise Value | $309.89B | $2.25B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
SoundHound AI (SOUN) trades at $5.52, down 1.95% amid bearish technical signals despite recent earnings beats. The company shows strong revenue growth with 2025 revenue of $168.92M and projected 2026 revenue of $203M, but faces significant profitability challenges with a -67.45% net income margin. Recent developments include expansion into banking AI agents and the OASYS Edge embedded architecture launch for vehicles and smart devices.
While analyst consensus remains bullish with a $9.33 price target (75% buy ratings), the stock faces headwinds from persistent losses, negative cash flow projections for 2026, and insider selling activity. The key investment thesis hinges on voice AI adoption growth versus the company's ability to achieve profitability amid high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
